Cartalax

Mechanism

Cartalax is a short three-amino-acid peptide bioregulator designed to support cartilage health and joint function by activating the genes responsible for cartilage repair and maintenance. It works at the DNA level to restore normal protein synthesis in cartilage cells (chondrocytes), helping to rebuild the extracellular matrix that gives cartilage its cushioning properties. Developed by Russian researchers as part of the Khavinson bioregulator peptide series, it has shown promise for osteoarthritis and age-related joint degeneration.

Effects

## Musculoskeletal/Cartilage System [Tier 2 - Small Human Studies/Russian Clinical Data] - Tripeptide bioregulator (Ala-Glu-Asp) developed at the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson laboratory) - Part of the "Khavinson peptide bioregulators" — short peptides theorized to interact directly with DNA regulatory regions to restore age-related gene expression changes - Targets cartilage tissue gene expression: upregulates collagen II, aggrecan, and proteoglycan synthesis in chondrocytes - Reduces cartilage degradation marker expression (MMP-3, MMP-13, ADAMTS-4/5) in cell culture models - Russian clinical data (limited by Western standards): improvements in joint pain scores and mobility in osteoarthritis patients - Represents the bioregulatory peptide approach to joint health — working at the gene expression level rather than the symptom level ## Connective Tissue/General [Tier 3 - Mechanistic/Theoretical] - May support broader connective tissue health beyond cartilage (tendons, ligaments, intervertebral discs share proteoglycan-dependent ECM) - Theoretical anti-aging effects on joint tissue through epigenetic modulation - Khavinson's bioregulatory theory: short peptides regulate gene expression in a tissue-specific manner by interacting with specific DNA sequences ## Anti-Aging/Longevity [Tier 3 - Theoretical/Animal Data] - Part of a class of bioregulatory peptides (alongside epithalon, vilon, testagen, etc.) studied for anti-aging effects - Khavinson's group published data on lifespan extension in animal models using bioregulatory peptide combinations - The specific contribution of cartalax to longevity vs. the other peptides in these combinations is unclear ## Immune/Anti-Inflammatory [Tier 3 - Mechanistic] - May reduce cartilage inflammation through NF-kB pathway modulation - Anti-inflammatory effects in chondrocyte cultures exposed to IL-1beta (osteoarthritis model) - Does not suppress systemic immune function — effects appear tissue-specific

Practitioner Guide

## Clinical Positioning Cartalax is a Russian bioregulatory peptide from the Khavinson school. It occupies a niche position in peptide therapy — used by practitioners who are familiar with the Russian bioregulator approach, which is well-established in Russian medicine but has limited recognition in Western clinical practice. It is typically used for joint/cartilage support in aging patients with osteoarthritis. ## Context: The Bioregulator Approach - Professor Vladimir Khavinson developed a series of short peptides (2-4 amino acids) at the St. Petersburg Institute of Bioregulation and Gerontology - Theory: specific short peptides interact with complementary DNA sequences in specific tissues, modulating gene expression back toward youthful patterns - These peptides are approved and widely used in Russian clinical practice - Western clinical data is limited — most evidence is published in Russian journals or presented at Russian conferences - This does NOT mean they don't work — it means the evidence base does not meet the standard of Western peer-reviewed RCTs ## Dosing ### Oral/Sublingual Protocol (Standard Bioregulator Approach) - 10-20mg oral or sublingual, daily - Duration: 10-20 day courses, repeated 2-4 times per year - Take on empty stomach for best absorption - This is the traditional Khavinson bioregulator dosing approach: short intensive courses repeated quarterly ### Injectable (Less Common) - Not typically available in injectable form through Western compounding pharmacies - Some practitioners source from Russian suppliers; quality control may be variable - If available: 10mg SC or IM daily for 10-20 days, repeated quarterly ## Patient Selection Best candidates: - Early-to-moderate osteoarthritis (Kellgren-Lawrence grade 1-3) - Patients interested in regenerative/bioregulatory approach rather than purely symptomatic treatment - Patients already using other Khavinson bioregulators (epithalon, testagen, etc.) - Those who want to complement BPC-157/TB-500 with a different mechanistic approach Less ideal: - Severe osteoarthritis (bone-on-bone — cartilage regeneration is unlikely at this stage) - Patients expecting rapid symptom relief (bioregulators work slowly, over months-years) - Patients who need rigorous evidence base before trying anything (redirect to glucosamine + chondroitin, PRP, or HA injections) ## Stacking - BPC-157 + Cartalax: BPC handles tissue repair and blood flow; cartalax supports cartilage-specific gene expression. Complementary mechanisms. - BPC-157 + Pentosan Polysulfate + Cartalax: triple joint protocol — repair (BPC), cartilage matrix protection (PPS), gene expression restoration (cartalax) - Cartalax + other bioregulators: epithalon (pineal), testagen (testes), vesugen (vascular) — the Russian longevity bioregulator stack ## What to Tell Patients "Cartalax is a very short peptide (just three amino acids) designed to interact with the genes in your cartilage cells to restore more youthful function. It comes from a Russian research tradition that has been studying these peptides for over 30 years. The approach is to take it in short courses — about 2-3 weeks at a time, a few times a year — to gradually shift your cartilage cells back toward healthier gene expression. It works slowly and subtly, so don't expect overnight relief." ## Timeline - First course (10-20 days): no immediate effects expected - After 2-3 courses (6-9 months): subtle improvement in joint comfort and stiffness, especially morning stiffness - After 1-2 years of quarterly courses: cumulative benefit in joint function and pain scores (per Russian clinical data) - This is a long-game intervention, not acute treatment

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  No human safety data during pregnancy. Bioregulator peptide modulating gene expression poses theoretical risk to fetal development.
  Action: Do not use during pregnancy.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Safety not established during lactation.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use.
  Action: Do not provide to individuals under 18.
• caution — General use
  Limited human safety data. Russian bioregulator peptide without large-scale clinical trials or international regulatory approval. Long-term safety profile not established.
  Action: Use with awareness of limited evidence base. Monitor for unexpected effects.

Stacks featuring this peptide

Research Summary

## Tier 1 — Limited Human Data (Primarily Russian) - Russian clinical studies (Khavinson et al.): improvement in joint pain scores and mobility in osteoarthritis patients after multiple courses - Studies typically small (20-60 patients), published in Russian journals - Safety: no significant adverse events reported in available literature - Approved for clinical use in Russia and several former Soviet states ## Tier 2 — In Vitro/Cell Culture Data - Chondrocyte cultures: cartalax increased collagen II and aggrecan expression by 20-40% - Reduced MMP-3 and MMP-13 expression (enzymes that degrade cartilage matrix) - Anti-inflammatory effects in IL-1beta-stimulated chondrocytes - DNA interaction studies (Khavinson lab): Ala-Glu-Asp sequence shown to interact with specific DNA sequences in regulatory regions of cartilage genes ## Tier 3 — Mechanistic/Theoretical - Bioregulatory peptide theory: short peptides complement specific DNA sequences and modulate gene expression epigenetically - This mechanism is supported by structural studies showing peptide-DNA interaction but the functional significance at physiological doses is debated - Part of a broader class of bioregulatory peptides with consistent theoretical framework ## Evidence Gaps - No Western peer-reviewed RCTs - Pharmacokinetics not characterized by Western standards - Oral bioavailability of a tripeptide is theoretically low (rapid proteolytic degradation) — how it exerts systemic effects on cartilage after oral administration is not well-explained - Mechanism of gene regulation by a free tripeptide is controversial in mainstream molecular biology - Dose-response not characterized - Long-term safety data limited - Independent replication of Russian clinical findings not available